12 October 2023, Munich – Due to the ongoing war between Israel and Hamas 1 2, we investigated the impact of the conflict on global pharmaceutical supply chains using the QYOBO platform.
We identified over 60 essential APIs manufactured in Israel. Only 4 APIs have more than 30% of their API manufacturing footprint in Israel, among them Amprolium, a commonly used veterinarian drug, and Atosiban, a pharmaceutical used in gynecology (see Figure 1).
Two APIs are manufactured exclusively in Israel, including APIs for two orphan drugs. Pegunigalsidase alfa (ElfabrioTM) is a treatment option for Fabry disease, and Taliglucerase alfa (ElelysoTM) for Morbus Gaucher. Both are produced by Protalix, located north-east of Haifa, close to the Lebanese border (see Figure 2).
In Lebanon, we identified two FDF manufacturing companies (ALGORITHM SAL and PHARMALINE SAL). However, they are based north of Beirut and therefore not directly in the currently affected area.
All in all, except for two drugs, we don’t expect significant supply chain disruptions on the API manufacturing side.
1 https://edition.cnn.com/2023/10/07/middleeast/sirens-israel-rocket-attack-gaza-intl-hnk/index.html
2 https://www.nytimes.com/article/israel-gaza-hamas-what-we-know.html
About QYOBO GmbH
QYOBO’s mission is to improve access to essential medication for everyone by contributing to a more transparent, efficient and robust supply of pharmaceutical and chemical raw materials.
For this purpose, we’ve developed the QYOBO market analytics platform for APIs, intermediates and chemicals. From millions of trade, regulatory and financial datasets scattered around the world, our big data algorithms derive unique, actionable insights on market prices and trends, suggest suitable partners for your business and automate data-heavy workflows in procurement, supply chain and business development.
Founded in June 2019 and based in Munich, our company is pursuing its mission collaboratively with its international clients and has been recognized with numerous awards including the BASF market challenge and the Digital Innovation award 2020 by the German Federal Ministry for Economic Affairs & Energy (BMWi).
Disclaimer:
The information in this article is not intended to be used for medication purposes. Please do not self-medicate and consult a physician/doctor for any questions with regard to your personal medical needs. This assessment has been prepared adhering to the highest quality standards based on a variety of external data sources (see sources) with the purpose of making distributed information accessible to a broader audience. The information contained in this document is provided on an “as is” basis and QYOBO GmbH assumes no responsibility or liability for the completeness, accuracy, usefulness or timeliness of the information provided. This article contains links to external websites operated by third parties upon which QYOBO GmbH has no influence. QYOBO GmbH does not assume any guarantee or liability for third party content.
For further information please contact:
Ms. Sandra Fill,
Public relations,
QYOBO GmbH
